Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase 3 -studie for å vurdere CYB003 i stor depressiv lidelse (EMBRACE)

12. november 2026 oppdatert av: Cybin IRL Limited

En effektivitet og sikkerhet, fase III, multisenter, dobbeltblind, randomisert kontrollert studie som sammenligner 2 aktive doser av CYB003 og placebo hos kvalifiserte deltakere med stor depressiv lidelse

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

330

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Rekruttering
        • Royal Prince Alfred Hospital
        • Hovedetterforsker:
          • Nicholas Glozier
    • Queensland
      • Maroochydore, Queensland, Australia, 4558
        • Rekruttering
        • Thompson Brain & Mind Healthcare (TBMH)
        • Hovedetterforsker:
          • Adem Can
        • Ta kontakt med:
        • Ta kontakt med:
    • Victoria
      • Melbourne, Victoria, Australia, 3004
      • Melbourne, Victoria, Australia, 3053
        • Rekruttering
        • Neurocentrix Research
        • Hovedetterforsker:
          • David Barton
        • Ta kontakt med:
        • Ta kontakt med:
      • Notting Hill, Victoria, Australia, 3168
        • Rekruttering
        • Monash University - Notting Hill
        • Ta kontakt med:
        • Hovedetterforsker:
          • Paul Liknaitzky
    • Alabama
      • Birmingham, Alabama, Forente stater, 35209
        • Rekruttering
        • UAB Psychiatry and Behavioral Neurology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Peter Hendricks
        • Ta kontakt med:
    • Arizona
      • Gilbert, Arizona, Forente stater, 85234
        • Rekruttering
        • Lighthouse Psychiatry
        • Ta kontakt med:
        • Hovedetterforsker:
          • Frank Genova
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72204
        • Tilbaketrukket
        • Pillar Clinical Research - Little Rock
    • California
      • Glendale, California, Forente stater, 91206
        • Rekruttering
        • Behavioral Research Specialists, LLC
        • Hovedetterforsker:
          • Jesse Carr
        • Ta kontakt med:
      • Imperial, California, Forente stater, 92251
        • Tilbaketrukket
        • Sun Valley Research Center
      • Los Angeles, California, Forente stater, 90025
        • Rekruttering
        • CalNeuro Research Group
        • Hovedetterforsker:
          • Alexander Bystritsky
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90025
        • Rekruttering
        • Lipov Medical Group
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jacob Moussai
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • NRC Research Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Daniel Chueh
      • Orange, California, Forente stater, 92866
        • Rekruttering
        • ATP Clinical Research
        • Hovedetterforsker:
          • Gustavo Alva
        • Ta kontakt med:
      • San Juan Capistrano, California, Forente stater, 92675
        • Rekruttering
        • Inland Psychiatric Medical Group Inc (IPMG Research)
        • Hovedetterforsker:
          • Neelima Kunam
        • Ta kontakt med:
      • Santa Monica, California, Forente stater, 90404
        • Rekruttering
        • Psychedelic Science Institute
        • Hovedetterforsker:
          • Keith Heinzerling
        • Ta kontakt med:
      • Stanford, California, Forente stater, 94305
        • Tilbaketrukket
        • Stanford University
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06511
        • Rekruttering
        • Yale School of Medicine - Yale Program for Psychedelic Science
        • Hovedetterforsker:
          • Ben Kelmendi
        • Ta kontakt med:
          • Daidre Chamberlain
          • Telefonnummer: 203-693-1591
          • E-post: enact@yale.edu
        • Ta kontakt med:
    • Florida
      • Jacksonville, Florida, Forente stater, 32256
        • Rekruttering
        • CNS Healthcare
        • Ta kontakt med:
          • Telefonnummer: 904-281-5757
        • Hovedetterforsker:
          • John Mark Joyce
      • Maitland, Florida, Forente stater, 32751
        • Rekruttering
        • Accel Research Sites - Maitland
        • Ta kontakt med:
          • Telefonnummer: 407-644-1165
        • Hovedetterforsker:
          • Andrea Marrafino
      • Naples, Florida, Forente stater, 34105
        • Rekruttering
        • Aqualane Clinical Research
        • Hovedetterforsker:
          • Matthew Baker
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33634
        • Rekruttering
        • K2 Medical Research Tampa
        • Hovedetterforsker:
          • Kelley Wilson
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30329
        • Tilbaketrukket
        • Emory University Dept of Psychiatry and Behavioral Studies
      • Marietta, Georgia, Forente stater, 30060
        • Rekruttering
        • Psych Atlanta
        • Hovedetterforsker:
          • Michael Banov
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Rekruttering
        • Rush University
        • Hovedetterforsker:
          • Joshua Eloge
        • Ta kontakt med:
    • Louisiana
      • Marrero, Louisiana, Forente stater, 70006
        • Tilbaketrukket
        • Tandem Clinical Research
      • New Orleans, Louisiana, Forente stater, 70115
        • Rekruttering
        • Atlas Psychiatry
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nicholas Pejic
    • Maryland
      • Baltimore, Maryland, Forente stater, 21224
        • Tilbaketrukket
        • Johns Hopkins Medicine
      • Rockville, Maryland, Forente stater, 20850
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02116
        • Rekruttering
        • Adams Clinical Boston
        • Hovedetterforsker:
          • Darin Dougherty
        • Ta kontakt med:
      • Watertown, Massachusetts, Forente stater, 02472
        • Rekruttering
        • Adams Clinical Watertown
        • Hovedetterforsker:
          • Stephanie Ellickson
        • Ta kontakt med:
    • Minnesota
      • Eden Prairie, Minnesota, Forente stater, 55347
        • Rekruttering
        • Institute for Integrative Therapies
        • Hovedetterforsker:
          • Manoj Doss
        • Ta kontakt med:
      • Golden Valley, Minnesota, Forente stater, 55427
        • Har ikke rekruttert ennå
        • The Remedy Mental Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wayne Bentham
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89119
        • Rekruttering
        • Redbird Research, LLC
        • Hovedetterforsker:
          • Jelena Kunovac
        • Ta kontakt med:
    • New Jersey
      • Toms River, New Jersey, Forente stater, 08755
        • Rekruttering
        • Bio Behavioral Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ashok Patel
    • New York
      • New York, New York, Forente stater, 10032
        • Har ikke rekruttert ennå
        • New York State Psychiatric Institute
        • Hovedetterforsker:
          • Natalie Gukasyan
        • Ta kontakt med:
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Adams Clinical Harlem
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wesley Gregory
      • The Bronx, New York, Forente stater, 10461
        • Rekruttering
        • Adams Clinical Bronx
        • Hovedetterforsker:
          • Shama Farooq
        • Ta kontakt med:
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73112
        • Tilbaketrukket
        • SP Research PLLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Adams Clinical Philadelphia
        • Hovedetterforsker:
          • Cassie Blanchard
        • Ta kontakt med:
      • Philadelphia, Pennsylvania, Forente stater, 19462
        • Rekruttering
        • Flourish Research Philadelphia
        • Hovedetterforsker:
          • Rachna Saralkar
        • Ta kontakt med:
          • Telefonnummer: 215-614-5606
    • Texas
      • Austin, Texas, Forente stater, 78737
        • Tilbaketrukket
        • Austin Clinical Trial Partners
      • DeSoto, Texas, Forente stater, 75115
        • Rekruttering
        • Adams Clinical Dallas
        • Hovedetterforsker:
          • Rajinder Shiwach
        • Ta kontakt med:
      • Fort Worth, Texas, Forente stater, 76104
        • Tilbaketrukket
        • North Texas Clinical Trials
      • Houston, Texas, Forente stater, 77046
        • Rekruttering
        • Brain Health Consultants and TMS Center
        • Hovedetterforsker:
          • Lauren Marangell
        • Ta kontakt med:
      • San Antonio, Texas, Forente stater, 78229
    • Washington
      • Everett, Washington, Forente stater, 98201
        • Har ikke rekruttert ennå
        • Core Clinical Research
        • Ta kontakt med:
        • Hovedetterforsker:
          • James Knutson
      • Seattle, Washington, Forente stater, 98104
        • Rekruttering
        • Seattle Neuropsychiatric Treatment Center
        • Hovedetterforsker:
          • Rebecca Allen
        • Ta kontakt med:
      • Athens, Hellas, 12462
        • Rekruttering
        • Attikon University Hospital
        • Hovedetterforsker:
          • Nikolaos Smyrnis
        • Ta kontakt med:
      • Athens, Hellas, 11528
        • Rekruttering
        • Eginitio Hospital
        • Hovedetterforsker:
          • Nikos Stefanis
        • Ta kontakt med:
      • Thessaloniki, Hellas, 56404
        • Rekruttering
        • Papageorgiou General Hospital
        • Hovedetterforsker:
          • Georgios Papazisis
        • Ta kontakt med:
      • Dublin, Irland, D24 WK80
        • Rekruttering
        • Sheaf House - Tallaght Adult Mental Health Service
        • Hovedetterforsker:
          • John Kelly
        • Ta kontakt med:
      • Galway, Irland, H91 VE03
        • Rekruttering
        • La Nua Day Hospital Mental Health Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Shane McInerney
      • Bialystok, Polen, 15-272
        • Tilbaketrukket
        • Uniwersytecki Szpital Kliniczny W Białymstoku
      • Bydgoszcz, Polen, 85-133
        • Rekruttering
        • Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
        • Ta kontakt med:
        • Hovedetterforsker:
          • Katarzyna Lachut
      • Gdansk, Polen, 80-546
        • Rekruttering
        • Centrum Badan Klinicznych PI-House Sp. z o.o
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hanna Badzio-Jagiello
      • Gdansk, Polen, 80-214
        • Har ikke rekruttert ennå
        • UCK
        • Hovedetterforsker:
          • Wieslaw Jerzy Cubala
        • Ta kontakt med:
      • Warsaw, Polen, 02-957
        • Har ikke rekruttert ennå
        • Department of Pharmacology and Physiology of CNS
        • Hovedetterforsker:
          • Justyna Holka-Pokorska
      • Warsaw, Polen, 02-172
        • Rekruttering
        • MTZ Clinical Research Powered by Pratia
        • Hovedetterforsker:
          • Monika Gawlowicz
      • Cambridge, Storbritannia, CB1 2EU
        • Rekruttering
        • Cambridge University Hospital NHS
        • Hovedetterforsker:
          • Liliana Galindo
        • Ta kontakt med:
        • Ta kontakt med:
      • Doncaster, Storbritannia, DN4 8QN
        • Rekruttering
        • Clerkenwell Health - Doncaster
        • Hovedetterforsker:
          • Paul Morrison
        • Ta kontakt med:
      • Edinburgh, Storbritannia, EH16 4TJ
        • Har ikke rekruttert ennå
        • NHS Research Scotland
        • Hovedetterforsker:
          • Donald MacIntyre
        • Ta kontakt med:
      • Glasgow, Storbritannia, G51 4TF
        • Har ikke rekruttert ennå
        • Queen Elizabeth University Hospital
        • Hovedetterforsker:
          • Maytal Wolfe
        • Ta kontakt med:
      • Liverpool, Storbritannia, L7 8XP
        • Har ikke rekruttert ennå
        • Royal Liverpool Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Fabian Devlin
      • London, Storbritannia, EC2Y 8EA
        • Rekruttering
        • St Pancras Clinical Research
        • Hovedetterforsker:
          • Martin Johnson
        • Ta kontakt med:
      • London, Storbritannia, W1U 6RP
      • London, Storbritannia, W1G9 RU
        • Rekruttering
        • Re:Cognition Health
        • Hovedetterforsker:
          • Dimitrios Paschos
        • Ta kontakt med:
          • Telefonnummer: +44-0800-802-1030
      • London, Storbritannia, SE5 9RS
      • London, Storbritannia, W1G 8DR
        • Tilbaketrukket
        • Clerkenwell Health - Welbeck Street
      • Newcastle upon Tyne, Storbritannia, NE4 5PL
      • Reading, Storbritannia, RG7 8PA
        • Rekruttering
        • Ascend Clinical Research
        • Hovedetterforsker:
          • Pamela Walters
        • Ta kontakt med:
      • Sheffield, Storbritannia, S4 7QQ
      • Prague, Tsjekkia
        • Har ikke rekruttert ennå
        • Institute of neuropsychiatric Care (INEP)
        • Hovedetterforsker:
          • Alexander Nawka
        • Ta kontakt med:
      • Prague, Tsjekkia
        • Har ikke rekruttert ennå
        • Psyon s.r.o.
        • Hovedetterforsker:
          • Tomas Palenicek
        • Ta kontakt med:
      • Předměstí, Tsjekkia
        • Har ikke rekruttert ennå
        • A-SHINE s.r.o.
        • Hovedetterforsker:
          • Lubos Janu
        • Ta kontakt med:
      • Berlin, Tyskland, 10117
        • Har ikke rekruttert ennå
        • Charité Universitaetsmedizin Berlin
        • Hovedetterforsker:
          • Michael Koslowski
        • Ta kontakt med:
      • Frankfurt am Main, Tyskland, 60528
        • Har ikke rekruttert ennå
        • University Hospital Frankfurt
        • Hovedetterforsker:
          • Andreas Reif
        • Ta kontakt med:
      • Mannheim, Tyskland, 68159
        • Har ikke rekruttert ennå
        • Central Institute of Mental Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gerhard Grüender
    • Saarland
      • Homburg, Saarland, Tyskland, 66421
        • Har ikke rekruttert ennå
        • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
        • Hovedetterforsker:
          • Matthias Riemenschneider
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Age18 to 85 years.
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Moderate to severe depression at Screening and Baseline, independently confirmed.
  • Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
  • Participants have a presence or relevant history of organic brain disorders.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
  • Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Eksperimentell: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Placebo komparator: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Manualized psychological support performed by facilitator.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Montgomery-Asberg Depression Scale (MADRS)
Tidsramme: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity.

The total score ranges 0-60, higher scores denote greater severity.

Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The Beck Depression Inventory - Second Edition (BDI-II)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.

Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0.

Day -1, Day 21, Day 42 and Day 84/End of Trial.
The Clinical Global Impression Scale (CGI-S)
Tidsramme: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.

The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index.

Only the severity of illness ang global improvement measures will be utilized for this trial.

Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:

  1. = Normal, not at all ill
  2. = Borderline ill
  3. = Mildly ill
  4. = Moderately ill
  5. = Markedly ill
  6. = Severely ill
  7. = Among the most extremely ill patients
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Tidsramme: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms.

Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows:

Scores represent:

0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety

Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities.

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.

Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70

Day -1, Day 21, Day 42 and Day 84/End of Trial.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Felix Mazer, Cybin IRL Limited

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. desember 2025

Primær fullføring (Antatt)

7. juni 2027

Studiet fullført (Antatt)

9. august 2027

Datoer for studieregistrering

Først innsendt

21. januar 2025

Først innsendt som oppfylte QC-kriteriene

21. januar 2025

Først lagt ut (Faktiske)

27. januar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere